Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 34

1.

ATRX In-Frame Fusion Neuroblastoma Is Sensitive to EZH2 Inhibition via Modulation of Neuronal Gene Signatures.

Qadeer ZA, Valle-Garcia D, Hasson D, Sun Z, Cook A, Nguyen C, Soriano A, Ma A, Griffiths LM, Zeineldin M, Filipescu D, Jubierre L, Chowdhury A, Deevy O, Chen X, Finkelstein DB, Bahrami A, Stewart E, Federico S, Gallego S, Dekio F, Fowkes M, Meni D, Maris JM, Weiss WA, Roberts SS, Cheung NV, Jin J, Segura MF, Dyer MA, Bernstein E.

Cancer Cell. 2019 Nov 11;36(5):512-527.e9. doi: 10.1016/j.ccell.2019.09.002. Epub 2019 Oct 17.

PMID:
31631027
2.

Biodistribution and Dosimetry of Intraventricularly Administered 124I-Omburtamab in Patients with Metastatic Leptomeningeal Tumors.

Pandit-Taskar N, Zanzonico PB, Kramer K, Grkovski M, Fung EK, Shi W, Zhang Z, Lyashchenko SK, Vietri SM, Fung AM, Pentlow KS, Carrasquillo JA, Lewis JS, Larson SM, Cheung NV, Humm JL.

J Nucl Med. 2019 Aug 12. pii: jnumed.118.219576. doi: 10.2967/jnumed.118.219576. [Epub ahead of print]

PMID:
31405921
3.

Exploiting Signaling Pathways and Immune Targets Beyond the Standard of Care for Ewing Sarcoma.

Casey DL, Lin TY, Cheung NV.

Front Oncol. 2019 Jun 19;9:537. doi: 10.3389/fonc.2019.00537. eCollection 2019. Review.

4.

Telomere Trimming and DNA Damage as Signatures of High Risk Neuroblastoma.

Yu EY, Cheung IY, Feng Y, Rabie MO, Roboz GJ, Guzman ML, Cheung NV, Lue NF.

Neoplasia. 2019 Jul;21(7):689-701. doi: 10.1016/j.neo.2019.04.002. Epub 2019 May 23.

5.

Targeted radioimmunotherapy for embryonal tumor with multilayered rosettes.

Bailey K, Pandit-Taskar N, Humm JL, Zanzonico P, Gilheeney S, Cheung NV, Kramer K.

J Neurooncol. 2019 May;143(1):101-106. doi: 10.1007/s11060-019-03139-6. Epub 2019 Mar 16.

PMID:
30879172
6.

Reduced-Dose Radiation Therapy to the Primary Site is Effective for High-Risk Neuroblastoma: Results From a Prospective Trial.

Casey DL, Kushner BH, Cheung NV, Modak S, Basu EM, Roberts SS, LaQuaglia MP, Wolden SL.

Int J Radiat Oncol Biol Phys. 2019 Jun 1;104(2):409-414. doi: 10.1016/j.ijrobp.2019.02.004. Epub 2019 Feb 11.

PMID:
30763661
7.

Theranostic pretargeted radioimmunotherapy of internalizing solid tumor antigens in human tumor xenografts in mice: Curative treatment of HER2-positive breast carcinoma.

Cheal SM, Xu H, Guo HF, Patel M, Punzalan B, Fung EK, Lee SG, Bell M, Singh M, Jungbluth AA, Zanzonico PB, Piersigilli A, Larson SM, Cheung NV.

Theranostics. 2018 Oct 6;8(18):5106-5125. doi: 10.7150/thno.26585. eCollection 2018.

8.

Adoptive immunotherapy with haploidentical natural killer cells and Anti-GD2 monoclonal antibody m3F8 for resistant neuroblastoma: Results of a phase I study.

Modak S, Le Luduec JB, Cheung IY, Goldman DA, Ostrovnaya I, Doubrovina E, Basu E, Kushner BH, Kramer K, Roberts SS, O'Reilly RJ, Cheung NV, Hsu KC.

Oncoimmunology. 2018 May 10;7(8):e1461305. doi: 10.1080/2162402X.2018.1461305. eCollection 2018.

9.

Development of a Tetravalent Anti-GPA33/Anti-CD3 Bispecific Antibody for Colorectal Cancers.

Wu Z, Guo HF, Xu H, Cheung NV.

Mol Cancer Ther. 2018 Oct;17(10):2164-2175. doi: 10.1158/1535-7163.MCT-18-0026. Epub 2018 Aug 6.

10.

Convection-enhanced delivery for diffuse intrinsic pontine glioma: a single-centre, dose-escalation, phase 1 trial.

Souweidane MM, Kramer K, Pandit-Taskar N, Zhou Z, Haque S, Zanzonico P, Carrasquillo JA, Lyashchenko SK, Thakur SB, Donzelli M, Turner RS, Lewis JS, Cheung NV, Larson SM, Dunkel IJ.

Lancet Oncol. 2018 Aug;19(8):1040-1050. doi: 10.1016/S1470-2045(18)30322-X. Epub 2018 Jun 18. Erratum in: Lancet Oncol. 2018 Aug;19(8):e382.

11.

A potent tetravalent T-cell-engaging bispecific antibody against CD33 in acute myeloid leukemia.

Hoseini SS, Guo H, Wu Z, Hatano MN, Cheung NV.

Blood Adv. 2018 Jun 12;2(11):1250-1258. doi: 10.1182/bloodadvances.2017014373.

12.

Treatment and outcome of adult-onset neuroblastoma.

Suzuki M, Kushner BH, Kramer K, Basu EM, Roberts SS, Hammond WJ, LaQuaglia MP, Wolden SL, Cheung NV, Modak S.

Int J Cancer. 2018 Sep 1;143(5):1249-1258. doi: 10.1002/ijc.31399. Epub 2018 Apr 6.

13.

Dose-escalation is needed for gross disease in high-risk neuroblastoma.

Casey DL, Kushner BH, Cheung NV, Modak S, LaQuaglia MP, Wolden SL.

Pediatr Blood Cancer. 2018 Jul;65(7):e27009. doi: 10.1002/pbc.27009. Epub 2018 Feb 22.

14.

TCR-mimic bispecific antibodies targeting LMP2A show potent activity against EBV malignancies.

Ahmed M, Lopez-Albaitero A, Pankov D, Santich BH, Liu H, Yan S, Xiang J, Wang P, Hasan AN, Selvakumar A, O'Reilly RJ, Liu C, Cheung NV.

JCI Insight. 2018 Feb 22;3(4). pii: 97805. doi: 10.1172/jci.insight.97805. eCollection 2018 Feb 22.

15.

Radiation Therapy to Sites of Metastatic Disease as Part of Consolidation in High-Risk Neuroblastoma: Can Long-term Control Be Achieved?

Casey DL, Pitter KL, Kushner BH, Cheung NV, Modak S, LaQuaglia MP, Wolden SL.

Int J Radiat Oncol Biol Phys. 2018 Apr 1;100(5):1204-1209. doi: 10.1016/j.ijrobp.2018.01.008. Epub 2018 Jan 9.

16.

MYCN-amplified stage 2/3 neuroblastoma: excellent survival in the era of anti-GD2 immunotherapy.

Kushner BH, LaQuaglia MP, Modak S, Wolden SL, Basu EM, Roberts SS, Kramer K, Yataghene K, Cheung IY, Cheung NV.

Oncotarget. 2017 Aug 24;8(56):95293-95302. doi: 10.18632/oncotarget.20513. eCollection 2017 Nov 10.

17.

Phase I trial of anti-GD2 monoclonal antibody hu3F8 plus GM-CSF: Impact of body weight, immunogenicity and anti-GD2 response on pharmacokinetics and survival.

Cheung IY, Kushner BH, Modak S, Basu EM, Roberts SS, Cheung NV.

Oncoimmunology. 2017 Jul 31;6(11):e1358331. doi: 10.1080/2162402X.2017.1358331. eCollection 2017.

18.

Targeting Intracellular Antigens with pMHC-Binding Antibodies: A Phage Display Approach.

Wu Z, Santich BH, Liu H, Liu C, Cheung NV.

Methods Mol Biol. 2018;1701:255-269. doi: 10.1007/978-1-4939-7447-4_13.

PMID:
29116509
19.

Erratum to 'Limitations and opportunities for immune checkpoint inhibitors in pediatric malignancies' [Cancer Treat. Rev. 58C (2017) 22-33].

Park JA, Cheung NV.

Cancer Treat Rev. 2017 Nov;60:158. doi: 10.1016/j.ctrv.2017.09.007. Epub 2017 Oct 21. No abstract available.

PMID:
29033261
20.

A phase II study of radioimmunotherapy with intraventricular 131 I-3F8 for medulloblastoma.

Kramer K, Pandit-Taskar N, Humm JL, Zanzonico PB, Haque S, Dunkel IJ, Wolden SL, Donzelli M, Goldman DA, Lewis JS, Lyashchenko SK, Khakoo Y, Carrasquillo JA, Souweidane MM, Greenfield JP, Lyden D, De Braganca KD, Gilheeney SW, Larson SM, Cheung NV.

Pediatr Blood Cancer. 2018 Jan;65(1). doi: 10.1002/pbc.26754. Epub 2017 Sep 22.

21.

T cell engaging bispecific antibody (T-BsAb): From technology to therapeutics.

Wu Z, Cheung NV.

Pharmacol Ther. 2018 Feb;182:161-175. doi: 10.1016/j.pharmthera.2017.08.005. Epub 2017 Aug 20. Review.

22.

Curative Multicycle Radioimmunotherapy Monitored by Quantitative SPECT/CT-Based Theranostics, Using Bispecific Antibody Pretargeting Strategy in Colorectal Cancer.

Cheal SM, Fung EK, Patel M, Xu H, Guo HF, Zanzonico PB, Monette S, Wittrup KD, Cheung NV, Larson SM.

J Nucl Med. 2017 Nov;58(11):1735-1742. doi: 10.2967/jnumed.117.193250. Epub 2017 Jul 13.

23.

Limitations and opportunities for immune checkpoint inhibitors in pediatric malignancies.

Park JA, Cheung NV.

Cancer Treat Rev. 2017 Jul;58:22-33. doi: 10.1016/j.ctrv.2017.05.006. Epub 2017 Jun 1. Review. Erratum in: Cancer Treat Rev. 2017 Nov;60:158.

24.

A phase I study of single-agent perifosine for recurrent or refractory pediatric CNS and solid tumors.

Becher OJ, Millard NE, Modak S, Kushner BH, Haque S, Spasojevic I, Trippett TM, Gilheeney SW, Khakoo Y, Lyden DC, De Braganca KC, Kolesar JM, Huse JT, Kramer K, Cheung NV, Dunkel IJ.

PLoS One. 2017 Jun 5;12(6):e0178593. doi: 10.1371/journal.pone.0178593. eCollection 2017.

25.

Immunotherapy of hepatocellular carcinoma using chimeric antigen receptors and bispecific antibodies.

Hoseini SS, Cheung NV.

Cancer Lett. 2017 Jul 28;399:44-52. doi: 10.1016/j.canlet.2017.04.013. Epub 2017 Apr 17. Review.

26.

Temporal stability and molecular persistence of the bone marrow plasma cell antibody repertoire.

Wu GC, Cheung NV, Georgiou G, Marcotte EM, Ippolito GC.

Nat Commun. 2016 Dec 21;7:13838. doi: 10.1038/ncomms13838.

27.

A phase I/Ib trial targeting the Pi3k/Akt pathway using perifosine: Long-term progression-free survival of patients with resistant neuroblastoma.

Kushner BH, Cheung NV, Modak S, Becher OJ, Basu EM, Roberts SS, Kramer K, Dunkel IJ.

Int J Cancer. 2017 Jan 15;140(2):480-484. doi: 10.1002/ijc.30440. Epub 2016 Sep 30.

28.

Theranostic pretargeted radioimmunotherapy of colorectal cancer xenografts in mice using picomolar affinity ⁸⁶Y- or ¹⁷⁷Lu-DOTA-Bn binding scFv C825/GPA33 IgG bispecific immunoconjugates.

Cheal SM, Xu H, Guo HF, Lee SG, Punzalan B, Chalasani S, Fung EK, Jungbluth A, Zanzonico PB, Carrasquillo JA, O'Donoghue J, Smith-Jones PM, Wittrup KD, Cheung NV, Larson SM.

Eur J Nucl Med Mol Imaging. 2016 May;43(5):925-937. doi: 10.1007/s00259-015-3254-8. Epub 2015 Nov 24.

29.

Antibody induced pain in children: An opportunity to study pain mechanism, IgG design and analgesics.

Cheung NV.

Pediatr Blood Cancer. 2015 Feb;62(2):186-187. doi: 10.1002/pbc.25320. Epub 2014 Nov 8. No abstract available.

PMID:
25382406
30.

Local control with multimodality therapy for stage 4 neuroblastoma.

Wolden SL, Gollamudi SV, Kushner BH, LaQuaglia M, Kramer K, Rosen N, Abramson S, Cheung NV.

Int J Radiat Oncol Biol Phys. 2000 Mar 1;46(4):969-74.

PMID:
10705019
31.

Targeting of small-cell lung cancer using the anti-GD2 ganglioside monoclonal antibody 3F8: a pilot trial.

Grant SC, Kostakoglu L, Kris MG, Yeh SD, Larson SM, Finn RD, Oettgen HF, Cheung NV.

Eur J Nucl Med. 1996 Feb;23(2):145-9.

PMID:
8925848
32.

Reassessment of patient response to monoclonal antibody 3F8.

Cheung NV, Lazarus H, Miraldi FD, Berger NA, Abramowsky CR, Saarinen UM, Spitzer T, Strandjord SE, Coccia PF.

J Clin Oncol. 1992 Apr;10(4):671-2. No abstract available.

PMID:
1548529
34.

A quantitative enzyme-linked immunosorbent assay for honeybee venom-specific immunoglobulin G.

Reid MJ, Kwasnicki JM, Cheung NV.

J Allergy Clin Immunol. 1982 Sep;70(3):191-8.

PMID:
6179974

Supplemental Content

Loading ...
Support Center